$2.58
4.44% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US8051111016
Symbol
SVRA

Savara, Inc. Stock price

$2.58
+0.07 2.79% 1M
-0.17 6.18% 6M
-0.49 15.96% YTD
-1.52 37.07% 1Y
+0.87 50.88% 3Y
+0.64 32.99% 5Y
-24.94 90.62% 10Y
-6,122.42 99.96% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.12 4.44%
ISIN
US8051111016
Symbol
SVRA
Industry

Key metrics

Basic
Market capitalization
$466.7m
Enterprise Value
$323.7m
Net debt
positive
Cash
$172.5m
Shares outstanding
172.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.2
Financial Health
Equity Ratio
80.5%
Return on Equity
-56.0%
ROCE
-61.4%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-108.8m | $-39.0m
EBIT
$-109.0m | $-115.9m
Net Income
$-101.9m | $-85.4m
Free Cash Flow
$-95.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-56.0% | 62.1%
EBIT
-55.9% | -12.5%
Net Income
-58.9% | 11.0%
Free Cash Flow
-57.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
$-0.6
Short interest
12.9%
Employees
59
Rev per Employee
$0.0
Show more

Is Savara, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Savara, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Savara, Inc. forecast:

11x Buy
79%
3x Hold
21%

Analyst Opinions

14 Analysts have issued a Savara, Inc. forecast:

Buy
79%
Hold
21%

Financial data from Savara, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
60% 60%
-
- Research and Development Expense 80 80
54% 54%
-
-109 -109
56% 56%
-
- Depreciation and Amortization 0.13 0.13
30% 30%
-
EBIT (Operating Income) EBIT -109 -109
56% 56%
-
Net Profit -102 -102
59% 59%
-

In millions USD.

Don't miss a Thing! We will send you all news about Savara, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Savara, Inc. Stock News

Neutral
Business Wire
25 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On July 15, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards cons...
Neutral
Accesswire
3 months ago
BOSTON, MA / ACCESS Newswire / May 28, 2025 / Block & Leviton is investigating Savara Inc. (Nasdaq:SVRA) for potential securities law violations. Investors who have lost money in their Savara Inc. investment should contact the firm to learn more about how they might recover those losses.
Neutral
GlobeNewsWire
3 months ago
ATLANTA, May 27, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) complied with federal securities laws. On May 27, 2025, Savara announced that it had received a refusal to file letter from the FDA for the Biologics License Application of MOLBREEVI as a therapy to treat patients with autoimmune pulmonary alveolar prote...
More Savara, Inc. News

Company Profile

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Head office United States
CEO Matthew Pauls
Employees 59
Founded 1995
Website savarapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today